The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) within the National Health Service (NHS ...

What this means in practice is that there is enough evidence to show that sparsentan provides benefits and value for money, so it can be used routinely if it is considered the most suitable ...

NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4 IgA nephropathy is characterised by the buildup of a faulty version of immunoglobulin A (IgA ...

What this means in practice is that there is enough evidence to show that sparsentan provides benefits and value for money, so it can be used routinely if it is considered the most suitable treatment ...

CSL Vifor expects to launch sparsentan in the UK in the second half of 2025; commercial stock will be available from July 2025. The articles, information, and content displayed on this webpage may ...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically ...

5 What this means in practice is that there is enough evidence to show that sparsentan provides benefits and value for money, so it can be used routinely if it is considered the most suitable ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...